Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review. [electronic resource]
Producer: 20190523Description: 764-774 p. digitalISSN:- 1952-4013
- Alemtuzumab -- therapeutic use
- Aminopterin -- analogs & derivatives
- Antimetabolites, Antineoplastic -- therapeutic use
- Antineoplastic Agents, Immunological -- therapeutic use
- Deoxycytidine -- analogs & derivatives
- Folic Acid Antagonists -- therapeutic use
- Humans
- Mycosis Fungoides -- drug therapy
- Retreatment
- Sezary Syndrome -- drug therapy
- Skin Neoplasms -- diagnostic imaging
- Gemcitabine
No physical items for this record
Publication Type: Comparative Study; Journal Article; Systematic Review
There are no comments on this title.
Log in to your account to post a comment.